Tag: Innovent

February 7, 2019 Off

Innovent can test its protein in patients with hemaological and advanced solid tumors

Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.

January 15, 2019 Off

China’s Innovent Biologics preparing to advance IBI188 into subsequent clinical trials in a variety of cancers

By Dino Mustafić

Innovent Biologics has dosed the first patient in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.